French Blood Establishment (EFS) & Brenus Pharma Partner for the GMP Production of STC-1010, an Innovative Therapy Against Colorectal Cancer
The French Blood Establishment (EFS) and Brenus Pharma announce their strategic partnership in the bioproduction of innovative therapy drugs (ITD), highlighting French expertise. This collaboration is part of a shared vision: developing the French bioproduction sector nationally and internationally.
EFS’ Cell Therapy and Engineering Unit (UTICELL), based in Saint-Ismier, France, shows recognized expertise in the cell therapy field since 2003 confirmed by a European GMP Certification issued by the ANSM in 2015 for manufacturing, control and storage sites for MTIs. UTICELL also benefits from EFS’ four other certified sites’ expertise.
Brenus’s proprietary platform passed key regulatory milestones in 2022 (FDA Pre-IND, EMA Scientific-Advice) and the two synergistic entities have been collaborating effectively for several months to produce GMPs batches through a first scale-up.
This public-private partnership aims for a long-term perspective and will lead in 2023 to the production of clinical batches for the Fist-In-Human study of STC-1010, Brenus Pharma's lead candidate, targeting colorectal cancer.
"This collaboration is the result of a scientific and regulatory technical evaluation conducted with several CDMOs. The competitiveness, flexibility, and expertise of the EFS caught our attention. The UTICELL teams’ knowledge bring added value to the STC-1010 project's development, thanks to their unfailing proactivity and proposal strength," said Benoit Pinteur, Brenus Pharma's CSO.
"This collaboration reflects the importance of having both technical and scientific expertise in France to quickly advance the development of this promising drug and fulfill our public health mission. From the first exchanges with Brenus, we were impressed by the maturity of the STC-1010 project and convinced that through this collaboration, we could give patients a chance to fight their cancer," said Anaick MOISAN, Pharmacist Delegate, UTICEL EFS Rhône-Alpes.
ABOUT BRENUS
Brenus Pharma is developing first-in-class tumor-antigens focused immunotherapies for solid tumors’ treatment. Brenus has developed STC (Stimulated Tumor Cells), a technology platform mimicking relapsing conditions and enabling the education of patients' immune system, to fight the resistance mechanisms of tumor cells. www.brenus-pharma.com
ABOUT THE EFS
EFS is the public blood service in France. We are 10,000 professionals, including doctors, nurses, biologists, technicians, pharmacists, collection teams, researchers, administrative staff… driven by the same vital mission. We are present throughout the care chain and thus give blood the power to heal. efs.sante.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230327005465/en/
Contact information
For further information: contact@brenus-pharma.com ; charley.dubois@efs.sante.fr
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SmartStream Launches Latest Solution for Onboarding Cash Balances Faster With AI-Enabled Technology6.6.2023 09:53:00 CEST | Press release
SmartStream, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announces the latest version of SmartStream Air – with new AI functionality to onboard cash balances faster and more accurately, whilst further improving cash reconciliations. A new development team was set up to research and provide the new functionality in partnership with clients. If cash balances and/or positions are not managed correctly they will eventually lead to errors, financial losses, and even regulatory penalties. The key USP for SmartStream Air version 8 is for quick and easy onboarding of cash balances. The latest solution will continue to leverage its AI-enabled technology and exception management capabilities to provide users with the confidence to manage cash balances instantly. It is a great addition for existing clients, whilst providing a competitive advantage by outperforming slow, expensive, and ineffective systems. Jethro MacDonald, Head of Product Management – AI and Ma
Chatham Hires Jennifer McLellan as a Managing Director in Global ISDA and Regulatory Practice6.6.2023 09:00:00 CEST | Press release
Chatham Financial, a global leader in financial risk management advisory and technology solutions, is pleased to announce Jennifer McLellan is joining the company as a Managing Director in the global OTC derivative instruments, ISDA and regulatory practice. Jennifer established a leading practice in 2011 for law firm Dickson Minto, where she was the Head of Derivatives before joining Chatham. She has advised private equity sponsors, their portfolio investments, UK listed and private corporates, and an array of investment fund boards and managers on the end-user legal and regulatory issues around derivatives. Jennifer brings hands-on knowledge in navigating complicated cross-border M&A leveraged deals, including some of the largest European LBOs. She has advised on all stages of the deal lifecycle including diligence, deal contingent structures, running competitive multi-bank interest rate and FX hedging processes, as well as financial restructuring. On the funds side, Jennifer has a we
Intelsat To Deliver 2Ku Connectivity Upgrade to Japan Airlines6.6.2023 09:00:00 CEST | Press release
Intelsat, operator of the world’s largest integrated satellite and terrestrial network and leading provider of Inflight Connectivity (IFC) services, has reached an agreement with long-time customer Japan Airlines (JAL) to upgrade about 50 Boeing 737s and 767s to the company’s 2Ku inflight connectivity solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230606005202/en/ Intelsat To Deliver 2Ku Connectivity Upgrade to Japan Airlines (Photo: Business Wire) “We value the trust that JAL has placed in Intelsat throughout our 10-year relationship,” said Dave Bijur, senior vice president of Commercial for Intelsat Commercial Aviation. “JAL was Intelsat’s first non-U.S. commercial aviation customer, and we look forward to continuing to support JAL’s market-leading inflight connectivity service in Japan where their guests enjoy free service.” In addition to the fleet of Boeing 737s and 767s, JAL’s subsidiary airline, J-AIR Co. Lt
Discover ® Global Network Study Finds 93% of Global Fintechs Increased Reliance on Payment Networks Given the Current Economic Environment6.6.2023 07:02:00 CEST | Press release
Today, Discover shared a portion of the third annual Fintech State of the Union, the most comprehensive study of its kind in the industry, providing global perspectives from consumers, fintech vendors, and venture capitalists. The research study commissioned by Discover Global Network with 451 Research of S&P Global Market Intelligence surveyed global fintechs to identify emerging digital payments trends shaping the fintech ecosystem. Reliance on Payments Networks is Strong for Fintechs Per the study, fintechs are dependent on payments networks, with 93% saying the current economic environment has increased their business’s reliance on payments networks. Fintechs are looking for payments partners who are flexible (44%) and innovative (44%). Fintechs also say they benefit from payment networks the most through financial investment (42%), access to customers (38%), and technology enablement (38%). “As a payments network, it’s exciting to see both fintechs and venture capitalists lean int
Carbios Aims to be a Leader in Growing r-PET Market with an Ambition to Capture 8 to 12% Share by 2035 Through Licensing Model6.6.2023 06:45:00 CEST | Press release
Regulatory News: Carbios (Euronext Growth Paris: ALCRB), a biotech company pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, will hold its 2023 Strategic Update today at 2pm CET in which it provides details of its business model for 2030 and 2035. Carbios announces its ambition to be a leading player in the global r-PET market by capturing between 4 and 8% of market share by 2030 and between 8 and 12% by 2035. CLICK HERE TO JOIN THE WEBCAST AT 2pm CET OR TO VIEW THE REPLAY Emmanuel Ladent – Chief Executive Officer and the Carbios Leadership team 6 June 2023, from 2pm CET to 4pm CET (Paris Time) https://edge.media-server.com/mmc/p/u2qw4cir France Dial-in: +33 170918704 / UK Dial-in: +44 1 212818004 1. A VALUE-CREATING BUSINESS MODEL Carbios’ business model, based on the licensing of its unique PET biorecycling technology2, relies on a CapEx lean approach and 3 sources of revenue (upfront payments and two recur